AB Science Secures Clinical Trial Funding Insurance for ALS Phase III Study
AB Science announced a binding offer for Clinical Trial Funding Insurance from Medical & Commercial International Ltd. for its Phase III ALS trial evaluating masitinib. The policy covers up to EUR 39 million and becomes effective upon first patient enrollment.
AB Science SA, listed on Euronext under ticker FR0010557264, announced on April 16, 2026, that it has received a binding offer for Clinical Trial Funding Insurance (CTFI) from Medical & Commercial International Ltd. (MCI), Lloyd's Syndicate 1902, for its Phase III clinical trial AB23005 evaluating masitinib as an add-on therapy in Amyotrophic Lateral Sclerosis (ALS).
The insurance policy, arranged by Lloyd's broker Acrisure Re UK and its European affiliate Acrisure Re Netherlands, provides coverage with a limit of liability of EUR 25 million and potentially up to EUR 39 million against the full financial cost of clinical failure, with no deductible.
The policy becomes effective from the date the first patient is enrolled in the trial, and the premium is payable when AB Science initiates the ALS Phase III clinical trial and mobilizes the necessary financing. CTFI reimburses biopharmaceutical companies for costs incurred if a clinical trial fails to meet its pre-defined success criteria.
This arrangement allows AB Science to transfer financial risk to MCI in exchange for a one-time upfront premium.
MCI's diligence process included reviewing past clinical data, real-life data, trial design, and in-silico modelling before issuing the binding quotation. The offer remains valid and may be activated until December 31, 2026. Alain Moussy, CEO and co-founder of AB Science, stated, "AB Science is very proud to be one of the first companies in the world to benefit from this CTFI for a phase 3 in ALS.
" James Banks, co-founder of MCI, said, "We are thrilled to be able to support global drug development and facilitate lending through insurance. This approach helps companies raise capital and reduce equity dilution through downside protection, leaving greater control and ownership in the hands of the innovator.
AB Science has a truly exciting asset that has the potential to materially slow disease progression in ALS patients.
" Separately, AB Science has implemented a voluntary temporary halt in Europe of its clinical trials ahead of a strategic reorganization, according to the company.
Story Timeline
3 events- 2026-04-16 19:00 CET
AB Science provides an update on its clinical development program in Paris.
1 sourceAB Science SA - 2026-04-16
AB Science receives binding offer for Clinical Trial Funding Insurance from MCI for Phase III ALS trial AB23005.
1 sourceAB Science SA - 2026-04-16
AB Science implements voluntary temporary halt in Europe of clinical trials before strategic reorganization.
1 sourceAB Science SA
Potential Impact
- 01
The insurance coverage reduces AB Science's financial risk associated with the ALS Phase III trial.
- 02
The temporary halt in clinical trials in Europe could delay ongoing research activities pending reorganization.
- 03
The CTFI may facilitate AB Science's ability to raise capital while limiting equity dilution.
Transparency Panel
Related Stories
abcnews.go.comNPR Receives $113 Million in Private Donations After Federal Funding Cut
NPR announced it received $113 million in philanthropic donations from two donors, including an $80 million gift from Connie Ballmer and $33 million from an anonymous donor. The donations came months after the Trump administration ended federal funding for public media.
insightsonindia.comUK Drug and Food Shortages Linked to Strait of Hormuz Conflict
The ongoing conflict involving Iran's blockade of the Strait of Hormuz is raising concerns about shortages of medicines, jet fuel, and food supplies in the UK. Officials warn that disruptions to supply chains could lead to shortages as early as this summer.
NewsweekTrump’s Approval Rating Strengthens Among Republicans but Remains Negative Nationally
Recent polls show President Donald Trump’s approval rating among Republican voters has increased to above 80 percent, while his overall national approval remains below 40 percent. The data highlights a growing partisan divide ahead of the 2026 midterm elections.